The future of immunotherapy for diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Immunotherapy, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies, has transformed diffuse large B-cell lymphoma (DLBCL) treatment.
• Novel immunotherapeutic strategies are being investigated to benefit patients ineligible for conventional therapies due to age or health status.

Purpose of the Study:

• To review current and emerging immunotherapeutic strategies for diffuse large B-cell lymphoma (DLBCL).
• To explore the potential of combining innate and adaptive immune responses and other therapeutic modalities to overcome treatment resistance and improve patient outcomes.

Main Methods:

• Review of current literature on immunotherapy in DLBCL.
• Discussion of novel approaches including CAR T-cell therapy, bispecific antibodies, NK cell-engaging therapies, myeloid cell-engaging therapies, and immune checkpoint inhibitors.
• Exploration of combination strategies involving immunotherapy with other agents and targeting the tumor microenvironment.

Main Results:

• Current immunotherapies like anti-CD19 CAR T-cells and bispecific antibodies are significantly impacting DLBCL treatment.
• Emerging strategies leverage both adaptive and innate immunity (NK cells, macrophages) and target pathways like CD47/SIRPα.
• Combination therapies, including those with oncogenic pathway inhibitors, show promise for overcoming resistance and reprogramming the tumor microenvironment.

Conclusions:

• Immunotherapy continues to evolve, offering new hope for DLBCL patients.
• Harnessing both innate and adaptive immunity, alongside combination strategies, is crucial for advancing DLBCL treatment.
• Future research should focus on optimizing these approaches for improved efficacy and broader patient applicability.